Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Billions At Stake As Generic Approvals Open Up Japan Big Sellers

Japan has approved a new batch of first-time and other generic drugs that will be reimbursed and launched in June, putting at risk several billion dollars’ worth of combined sales of some major branded products.

Generic Drugs Japan

Mesoblast Eyes Japan Conditional Approval After New RA Cell Therapy Data

Mesoblast is looking at a possible conditional approval pathway in Japan for its cell therapy for rheumatoid arthritis, based on promising new results from a Phase II study that showed a durable response for at least nine months from a single “dose”.

Research & Development Clinical Trials

Novo Sees Brighter China Outlook As Volumes Rise

Novo Nordisk says its China business is regaining strength, helped by improved volumes and broad growth in the diabetes sector and despite pricing pressures, and sees a brighter outlook ahead of the local approval of Tresiba.

Commercial Companies

Sanofi Upbeat On China Growth, Investment Despite Q4 Weakness

Sanofi remains confident of its pharma business and growth prospects in China despite a decline in overall sales in this key emerging market in the fourth quarter.

China Commercial

Takeda Extends PRA Alliance To Japan With New JV

Takeda is setting up a new joint venture in Japan to extend its global clinical development partnership with PRA, as part of an ongoing R&D overhaul.

Research and Development Strategies Deals

J&J’s Stoffels On Actelion’s ‘Exquisite’ Researchers, India TB R&D Plans

J&J’s chief scientific officer Dr. Paul Stoffels tells Scrip that flexibility is a hallmark of how the company goes about its collaborations, including the new $30bn deal with Actelion. Stoffels is also hoping to progress the science for a new TB medicine via a unique collaboration in India.

Commercial Strategy
See All

Europe

Set Alert for Europe

Latest From Europe

New EU Nod For J&J/Genmab's Darzalex Brings It Closer To Rivals

The EU's CHMP has given the go ahead to extend the EU licence for Janssen/Genmab's Darzalex to include its use earlier in the treatment paradigm, bringing into line with the US label and its rivals.

Europe Drug Review

Busy In-Tray Awaits New EFPIA Boss Nathalie Moll

Nathalie Moll is moving on from leading the biotech industry body EuropaBio to be the next director general of EFPIA, the federation that represents the R&D-based pharmaceutical industry in Europe. With issues such as the forthcoming Brexit negotiations, the EU’s inquiry into medicines access and pricing, and the implementation of the new Clinical Trials Regulation on the agenda, Moll will have a lot of weighty dossiers to deal with.

Policy & Regulation Leadership

Rosalind Franklin Institute May Calm Industry’s Brexit Fears

The setting up of the Rosalind Franklin Institute to link up with one of the world’s largest electron microscopy centers in Harwell, Oxford, could bolster company sentiment towards UK R&D investment in a post-Brexit world.

Innovation Policy

Turkish Govt Using Purchasing To Foster Local Generic Production

Facing difficulties in attracting greenfield pharma investments in the production of original and high-tech drugs, the Turkish Government is leveraging its purchasing power for generics to encourage local manufacture in this sector. Faced with the threat of exclusion from reimbursement, some multinationals are now building up their capacity in the country.

Turkey Manufacturing

AstraZeneca Works To Replicate China Success In Russia

AstraZeneca sees similarities with China in the Russian market and is hoping to replicate its success there, says global product and portfolio strategy head Mark Mallon.

Commercial Strategy

Laying The Groundwork For Value-Based Healthcare In Europe

Elisabeth Aloy and David Pistor, healthcare and life sciences advisors at Monitor Deloitte, outline five design principles to create a value-based care project.

Market Access Reimbursement
See All

United States

Set Alert for United States

Latest From United States

Tepid Q3 For Sun But Momentum In Specialty Build-Up

Sun Pharma reported a decline in profits for the third quarter amid dull US and India growth and ongoing investments to prepare for a larger play in the specialty segment, where it hopes to scale up with a mix of organic and inorganic additions to its portfolio.

Commercial Generic Drugs

Carrots and Stick: Biopharma At The White House

Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.

Policy & Regulation Pricing Debate

Piramal Stays The M&A Course; Snaps Up Niche Mallinckrodt Assets

India’s Piramal group continues its buying spree, snapping up Mallinckrodt’s intrathecal therapy business, as it seeks limited competition niches to plough deeper into the $20bn-plus global generic injectable hospital drugs market.

Commercial Deals

Biocon Chief Sees Bright Future For Indian Pharma In Trump Era

Biocon’s chair and managing director, Kiran Mazumdar-Shaw, tells Scrip she sees a strong partnering role for Indian firms in the Trump regime, but adds that “carte blanche” pricing that innovator companies enjoyed could come under check.

Commercial United States

IDMA Meet: Trump, Protectionism, New Markets And Cricket

The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.

Commercial Strategy

GSK US Pharma President Jack Bailey On A “Dynamic” 2017

With new US President Trump in place, new corporate CEO Walmsley to take the reins in April and the opportunity for four US drug launches in 2017, GSK’s president of US Pharmaceuticals says he is preparing for an “intense” year.

Leadership Launches
See All
UsernamePublicRestriction

Register